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Interleukin 6 (IL-6) is a multifunctional cytokine produced
by a variety of lymphoid and non-lymphoid cells. It has been
recently shown that IL-6 induces growth and differentiation in
human B cells, promotes proliferation of certain hybridomas
and plasmacytomas, inhibits the growth of fibroblasts and
certain tumour cell lines, and induces the synthesis of certain
'acute phase' protein in liver cells (reviewed in Hirano et al.,
1990). Moreover, IL-6 has been also shown to act on lectin-
activated T cell-proliferation (Helle, 1989), on NK cells, and
as a helper factor for the in vitro induction of cytotoxic T
cells (Okada et al., 1988; Takai et al., 1988). Thus, IL-6
participates in the regulation of immune responses, acute
phase proteins (Ramadori et al., 1988) and may play a
central role in host defence mechanisms (Hirano et al., 1990).
In mice bearing transplantable solid tumours, increased
levels of circulating IL-6 are detected and directly correlate
with the extent of the tumour burden (McIntosh et al., 1989).
To the best of our knowledge only one study has investigated
IL-6 in patients with cancer and reported increased circu-
lating concentrations (Erroi et al., 1990).
We have investigated the IL-6 serum concentrations and
monocyte production in patients with advanced head and
neck cancer (HNC) in different stages of disease, in com-
parison to healthy subjects. In this paper we first report that
high amounts of IL-6 are detected in the sera of HNC
patients, and that in HNC patients an increased IL-6 pro-
duction by LPS activated monocytes takes place.
Monocytes were obtained from 19 male and three female
patients with larynx (n = 10) and oral cavity (n = 6) and six
oropharynx (n = 6) carcinoma and from 22 sex and age
matched healthy subjects free from infections and drugs in
the 2 weeks preceding blood sampling. Blood samples were
withdrawn from fasting subjects between 8 and 9 am, 2-3
days before operation or radiotherapy.
Mononuclear cells were separated from peripheral citrated
(1:9 v/v) blood, drawn in plastic syringes and anticoagulated
with citrate (1:9 v/v). After centrifuging at 120g for 10min,
at room temperature, platelet-rich plasma was discarded,
cells were resuspended in phosphate buffered-saline (PBS)
(pH 7.4) and centrifuged at 120 g for 10min and platelets
were removed. After dilution 1:2 with PBS, cells were layered
into Ficoll-Hypaque (Lymphoprep, Immuno, Austria) and
centrifuged at 400g for 20min at 22C. The cells at the
interface were carefully removed with sterile plastic pipettes
and washed by centrifuging at 400g for 20 min at 4°C with
PBS. Monocytes were separated from mononuclear cells by
adherence to plastic Petri dishes (Bevilacqua et al., 1981).
Petri dishes were precoated with gelatin (30 mg ml-', type II,
Sigma, St Louis, Mo) by incubating at 37C. After gelatin
removal plates were dried at 40°C for 2 h and incubated with
fresh sterile autologous plasma for 1 h at room temperature.
The mononuclear cells, resuspended in RPMI-1640, were
layered on Petri dishes and incubated for 1 h at 22°C. At the
end of incubation, the medium, containing mainly lympho-
cytes, was removed by aspirating. Plates were washed three
times with RPMI-1640 prewarmed to 3rC. Adherent cells
were detached by incubating with 10 ml of cold PBS-EDTA
(10 mM) for 20 min at 22'C. Detached cells were removed by
aspirating and centrifuged at 400 g at 4C and resuspended in
RPMI-1640 medium.
The monocytes prepared by plastic adherence were greater
than 96% non-specific esterase positive and more than 99%
viable by the trypan blue exclusion test. Moreover, mono-
cytes and lymphocytes were identified by flow cytometric
analysis (Orthocyte, Ortho Diagnostic System, Milan, Italy)
by employing a monocyte- and lymphocyte-reactive mono-
clonal antibody (OKM 14, OKT3 and OKPanB, Ortho Diag-
nostic System, Milan, Italy).
Monocytes (2 x 106 cells mll) were incubated for 4 h at
37C in a CO2 incubator in the presence and absence of LPS
10lgm1-' (Sigma, St Louis, Mo). After incubation cell
suspensions were centrifuged at 400 g for 20 min and super-
natants were collected and stored at - 70C until assayed.
IL-6 concentration was assayed by IL-6 specific immuno-
assay (ELISA by Quantikine R&D System, Minneapolis,
USA).
The statistical analysis of the results was done by the
Wilcoxon rank-sum test for unpaired data and Spearman's
rank correlation coefficient. All P values reported are two-
tailed with values of less than 0.05 considered statistically
significant. Results are given as mean ± standard error.
Freshly isolated human peripheral blood monocytes from
controls did not spontaneously release appreciable amounts
of IL-6, whereas in seven out of 22 patients low concentra-
tions (87.9 ± 32.5 pg 10-6 cells) of IL-6 were detected in
supernatants of monocytes in the absence of LPS.
IL-6 production by LPS stimulated monocytes of HNC
patients was significantly (P<0.0001) higher than those of
controls (475.2 ± 86.4 and 55.4 ± 10.1 pg 106 cells, respec-
tively), whereas no significant differences were observed in
relation to cancer stage (I-II (n = 10) vs III-IV (n = 12)
Stage: 485.9 ± 95.3 vs 466.3 ± 134.8 pg 10-6 cells) (Figure 1).
Moreover, IL-6 levels detected in the sera of HNSC
patients was significantly higher than those of controls
(93.9 ± 7.06 vs 3.16 ± 1.9, respectively; P<0.0001) (Figure
2). A significant linear (r = 0.75, P<0.0001) relationship has
been found between IL-6 activated monocyte production and
IL-6 serum levels in HNC patients and in control subjects.
Monocytes are the major source of IL-6 in whole blood
(Kato et al., 1990), so it is conceivable that the elevated IL-6
levels in serum stem, at least in part from the increased
spontaneous and LPS induced production by monocytes. In
vitro, monocytes from HNC patients produce elevated IL-6
amounts not only after endotoxin stimulation, but in 30% of
the patients there was a release of IL-6 in the absence of
LPS stimulation. However, it has to be considered that the
tumour-bearing state may prime cells, such as endothelial
cells and fibroblasts, capable of producing IL-6 for enhanced
release upon stimulation by other cytokines (Sanceau et al.,
1990; Jabloson et al., 1989; McIntosh et al., 1989) or other
occurring stimuli and IL-6 production by tumour itself is
another possible mechanism (Tabibzadhet et al., 1989; Sehgal
et al., 1987; Hirano et al., 1987; Jourdan et al., 1990).
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Recently, the rapid appearance of IL-6 in the peripheral
blood (Jabloson et al.. 1989) after in vivo administration of
rTNF-alpha has been reported as well as the observation that
distinct tumour cell membrane constituents may activate
monocyte enhancing TNF production (Jaemcke & Maennel.
1990). Interestingly, we have previously observed an in-
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Figue 2 IL-6 serum levels in control subjects and in patients
with head and neck cancer.
creased TNF production by penrpheral monocytes of patients
affected by the same neoplastic disease (Gallo et al., 1991).
Therefore, it is possible that increased IL-6 serum levels
and monocyte production could be the expression of auto-
crine induction of this cytokine via TNF or could be directly
related to tumour activation.
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